PARP inhibitors
MOMA Therapeutics to Develop New PARP1 Inhibitor in Homologous Recombination-Deficient Solid Tumors
The agreement adds a new asset to the firm's pipeline of therapies targeting DNA damage response.
Lessons from the Phase III ZEST trial could inform ongoing and future trials as they seek to use ctDNA to prove efficacy of novel adjuvant treatments.
Accent Therapeutics Treats First Patient in Phase I DHX9 Inhibitor Trial
The study is designed to evaluate the safety, tolerability, and preliminary efficacy of ATX-559 in certain biomarker-selected cancer patients.
Allarity Therapeutics Providing Biomarker Analysis Services to Biotech
The firm is now inking revenue-generating contracts with other biotech companies for its drug response prediction and gene expression analysis capabilities.
NGS Tumor Testing Gaps Persist in Metastatic Prostate, Urothelial Cancers
A retrospective health record analysis revealed an inconsistent rise in rates of next-generation sequencing testing in metastatic prostate cancer and advanced urothelial cancer.